Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
Go back to Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment| KARYOPHARM THERAP (NASDAQ: KPTI) | Delayed: 9.50 +0.50 (5.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.00 | 52 Week High | $19.41 | |||
| Open | $9.10 | 52 Week Low | $4.83 | |||
| Day High | $10.22 | P/E | N/A | |||
| Day Low | $9.04 | EPS | $-2.74 | |||
| Volume | 564,583 | |||||
